We have to understand that the autophagy process is often inhibited in tumor cells, which
causes the dying cells to release ATP and so reduces the therapeutic efficiency in the
immune system. Scientists have discovered a way of increasing the therapeutic response in
these cases. They inhibited the enzyme that breaks down extracellular ATP, thus increasing
the concentration of these energy-storing molecules within the tumor. They also noted that
by re-establishing higher concentrations of extracellular ARP, this increased recruiting of
immune cells and enhanced the effects of chemotherapy. So this could prove to be an
additional possibility of treatment for patients with types of cancer where there is little or no
autophagy. These efficient treatments are still at the highly experimental stage. Assessment
has still to be carried out in mice, followed by clinic tests on human subjects.
Publication
G. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents
in mice.
Michaud M, Martin I, Sukkuwala A, Adjemian S, Ma Y, Pellegati P, Shen S, Kepp 0, Scoazec M, Mignot G, Rello-
Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghirïnghelli F, Galluzzi L, di Virgilio F, Zitvogel L, Kroemer
G.
Science. 2011 Dec16;334:1573-1577
Guido Kroemer, M.D., Ph.D. PU-PH
Related themes
1 INSERM, U848, Villejuif, France
2 Université Paris Descartes, Sorbonne Paris Cité, Paris, France
3 Metabolomics Platform, Institut Gustave Roussy, Villejuif, France
4 Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
5 Centre de Recherche des Cordeliers, Paris, France
Contact presse
Université Paris Descartes
Alice Tschudy & Pierre-Yves Clausse
01 76 53 18 63/17 98
pressefclparisdescartes.fr